Early evaluation of tumour metabolic response using [18F]fluorodeoxyglucose and positron emission tomography: A pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas

British Journal of Cancer

Volumn 82, Issue 3, 2000, Pages 608-615

  Brock, C S ^a   Young, H ^a   Reilly, S M ^a   Matthews, J ^a   Osman, S ^a   Evans, H ^b   Newlands, E S ^b   Price, P M ^a,c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b CHARING CROSS HOSPITAL   (United Kingdom)

^c CLATTERBRIDGE HOSPITAL   (United Kingdom)

Author keywords

Glioma; Metabolic rate of glucose (MRGlu); Positron emission tomography; Temozolomide

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; TEMOZOLOMIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG RESPONSE; FEMALE; GLIOMA; GLUCOSE UTILIZATION; HUMAN; MALE; PHASE 2 CLINICAL TRIAL; PILOT STUDY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECURRENT CANCER; TIME; TREATMENT OUTCOME;

EID: 0033953623     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.1999.0971     Document Type: Article

References (44)

1. Alavi JB, Alavi A, Chawluk J, Kushner M, Powe J, Hickey W and Reivich M (1988) Positron emission tomography in patients with glioma. A predictor of prognosis Cancer 62: 1074-1078
2. Bennett MJ, Timperley WR, Taylor CB and Hill AS (1978) Isoenzymes of hexokinase in the developing, normal and neoplastic human brain. Eur J Cancer 14, 189-193
3. Bland JM and Altman DG (1986) Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1: 307-310
4. Blasberg RG, Groothuis DR and Molnar P (1981) The application of qualitative autoradiographic measurements in experimental brain tumours. Semin Neurol 1: 203-333
5. Bleehen NM, Freedman LS and Stenning SP (1989) A randomized study of CCNU with and without benznidazole in the treatment of recurrent grades 3 and 4 astrocytoma. Report to the Medical Research Council by the Brain Tumor Working Party. Int J Radiat Oncol Biol Phys 16: 1077-1081
6. Brown RS and Wahl RL (1993) Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer 72: 2979-2985
7. Brown RS, Leung JY, Fisher SJ, Frey KA, Ethier SP and Wahl RL (1996) Intratumoral distribution of tritiated-FDG in breast carcinoma: correlation between Glut-1 expression and FDG uptake. J Nucl Med 37: 1042-1047
8. Cairneross JG, Pexman JH, Rathbone MP and DelMaestro RF (1985) Postoperative contrast enhancement in patients with brain tumor. Ann Neurol 17: 570-572
9. Cairneross JG, Macdonald DR, Pexman JH and Ives FJ (1988) Steroid-induced CT changes in patients with recurrent malignant glioma. Neurology 38: 724-726
10. De Witte O, Hildebrand J, Luxen A and Goldman S (1994) Acute effect of carmustine on glucose metabolism in brain and glioblastoma. Cancer 74: 2836-2842
11. 18F]-fluorodeoxyglucose and positron emission tomography. Neurology 32: 1323-1329
12. Fischman AJ and Alpert NM (1993) FDG-PET in oncology: there's more to it than looking at pictures. J Nucl Med 34: 6-11
13. Fulham MJ, Brunetti A, Aloj L, Raman R, Dwyer AJ and Di Chiro G (1995) Decreased cerebral glucose metabolism in patients with brain tumours: an effect of cortocosteroids. J Neurosurg 83: 657-664
14. 18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 27: 235-238
15. Hamberg LM, Hunter GJ, Alpert NM, Choi NC, Babich JW and Fischman AJ (1994) The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? J Nucl Med 35: 1308-1312
16. Herholz K, Wienhard K and Heiss WD (1990) Validity of PET studies in brain tumors. Cerebrovasc Brain Metab Rev 2: 240-265
17. Herholz K, Rudolf J and Heiss WD (1992) FDG transport and phosphorylation in human gliomas measured with dynamic PET. J Neurosurg 12: 159-165.
18. Herholz K, Pietrzyk U, Voges J, Schroder R, Halber M, Treuer H, Sturm V and Heiss WD (1993) Correlation of glucose consumption and tumour cell density in astrocytomas. A stereotactic PET study. J Neurosurg 79: 853-858
19. Higashi K, Clavo AC and Wahl RL (1993) Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake [see comments]. J Nucl Med 34: 414-419
20. Holthoff VA, Herholz K, Berthold F, Widemann B, Schroder R, Neubauer I and Heiss WD (1993) In vivo metabolism of childhood posterior fossa tumors and primitive neuroectodermal tumors before and after treatment, Cancer 72: 1394-1403
21. Huang SC, Phelps ME, Hoffman EJ, Sideris K, Selin CJ and Kuhl DE (1980) Noninvasive determination of local cerebral metabolic rate of glucose in man Am J Physiol 238: E69-82
22. Ichiya Y, Kuwabara Y, Otsuka M, et al. (1991) Assessment of response to cancer therapy using fluorine-18-fluorodeoxyglucose and positron emission tomography. J Nucl Med 32: 1655-1660
23. Ishizu K, Nishizawa S, Yonekura Y, Sadato N, Magata Y, Tamaki N, Tsuchida T, Okazawg H, Miyatake S, Ishikawa M et al. (1994) Effects of hyperglycemia on FDG uptake in human brain and glioma [see comments]. J Nucl Med 35: 1104-1109
24. Jansson T, Westlin JE, Ahlstrom H, Lila A, Langstrom B and Bergh J (1995) Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? J Clin Oncol 13: 1470-1477
25. 18F]2-fluoro-2-deoxy-D-glucose: a comparison of different analytical methods. J Cerch Blood Flow Metab 7: 161-172
26. Lindholm P, Minn H, Leskinen KS, Bergman J, Ruotsalainen U and Joensuu H (1993) Influence of the blood glucose concentration on FDG uptake in cancer a PET study [see comments]. J Nucl Med 34: 1-6
27. Minn H, Joensuu H, Ahonen A and Klemi P (1988a) Fluorodeoxyglucose imaging: a method to assess the proliferate activity of human cancer in vivo. Comparison with DNA flow cytometry in head and neck tumours. Cancer 61: 1776-1781
28. Minn H, Paul R and Ahonen A (1988b) Evaluation of treatment response to radiotherapy in head and neek cancer with fluorine-18 fluorodeoxyglucose. J Nucl Med 29: 1521-1525
29. Newlands ES, Blackledge GR, Slack JA, Rustin GJ, Smith DB, Stuart NS, Quarterman CP, Hoffman R, Stevens MF, Brampton MH and Gibson AC (1992) Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 65: 287-291
30. Okada J, Yoshikawa K, Itami M, Imaseki K, Uno K, Itami J, Kuyama J, Mikata A and Arimizu N (1992) Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. J Nucl Med 33: 325-329
31. O'Reilly SM, Newlands ES, Glaser MG, Brampton M, Rice Edwards JM, Illingworth RD, Richards P, Kennard C, Colquhoun T and Lewis P (1993) Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours [published erratum appears in Eur J Cancer 29a: 1500]. Eur J Cancer 29a: 940-942
32. 18F]fluorodeoxyglucose and positron emission tomography in the evaluation of radiation necrosis of the brain. Radiology 144: 885-889
33. Phelps ME, Huang SC, Hoffman EJ, Selin C, Sokoloff L and Kuhl DE (1979) Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol 6: 371-388
34. Price P and Jones T (1995) Can positron emission tomography (PET) be used to detect subclinical response to cancer therapy? The EC PET Oncology Concerted Action and the EORTC PET Study Group. Eur J Cancer 31a: 1924-1927
35. Ranicar AS, Williams CW, Schnorr L, Clark JC, Rhodes CG, Bloomfield PM and Jones T (1991) The on-line monitoring of continuously withdrawn arterial blood during PET studies using a single BGO/photomultiplier assembly and non-stick tubing. Med Prog Technol 17: 259-264
36. 11C]deoxyglucose. J Cereb Blood Flow Metab 5: 179-192
37. Roelcke U, Blasberg RG, von Ammor K, Hofer S, Vontobel P, Maguire RP, Radii EW, Herman RP and Leenders KL (1998) Dexamethasone treatment and plasma glucose values: relevance for fluorine-18-fluorodeoxyglucose uptake measurements in gliomas. J Nucl Med 39: 879-884
38. Rozental JM, Levin RL, Nickles RJ and Dobkin JA (1989) Glucose uptake by gliomas after treatment. A positron emission tomographic study [see comments]. Arch Neurol 46: 1302-1307
39. 18F]fluorodeoxyglucose method. J Cereb Blood Flow Metab 12: 823-834
40. 11C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 28: 897-916
41. Spence AM, Muzi NT, Graham MM et al. (1998) Glucose metabolism in human malignant gliomas measured quantitatively with PET, 1-[C-11]Glucose and FDG: analysis of the FDG lumped constant. J Nucl Med 39: 440-448
42. Valk PE, Budinger TF, Levin VA, Silver P, Gutin PH and Doyle WL (1988) PET of malignant cerebral tumors after interstitial brachytherapy. Demonstration of metabolic activity and correlation with clinical outcome. J Neurosurg 69: 830-838
43. Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B and Cody R (1993) Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 11: 2101-2111
44. Woods RP, Cherry SR and Mazziotta JC (1992) Rapid automated alogorithm for aligning and reslicing PET images. J Comput A Tomogr 16: 620-633